Abstract
CT-P13 was the first infliximab biosimilar approved in Brazil. Approval was granted for all indications of the innovator. Despite similar efficacy and safety, vigilance remains essential.
Author supplied keywords
Cite
CITATION STYLE
APA
Teixeira, F. V. (2016). First biosimilar of infliximab approved in Brazil: response from the Brazilian IBD society. GaBI Journal. Pro Pharma Communications International. https://doi.org/10.5639/gabij.2016.0501.002
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free